<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01171950</url>
  </required_header>
  <id_info>
    <org_study_id>PED-001</org_study_id>
    <nct_id>NCT01171950</nct_id>
  </id_info>
  <brief_title>CentriMag Ventricular Assist System in Treating Failure-to-Wean From Cardiopulmonary Bypass for Pediatric Patients</brief_title>
  <official_title>CentriMag Ventricular Assist System (VAS): Treatment of Failure-to-Wean From Cardiopulmonary Bypass for Pediatric Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thoratec Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and effectiveness of the CentriMag&#xD;
      ventricular assist system to help pediatric patients who have experienced heart failure&#xD;
      during surgery and cannot be removed from cardiac bypass.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>30 days after device removal, or, induction of anesthesia for implant of a long-term device or heart transplant</time_frame>
    <description>In patients who recover and do not go on to transplantation or a long-term device:&#xD;
• Survival 30 days after removal of the CentriMag VAS or to discharge, whichever is longer.&#xD;
In patients who do not recover:&#xD;
• Ability to be removed from the CentriMag VAS and survive to induction of anesthesia for implantation of a long-term device or heart transplantation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of end-organ function</measure>
    <time_frame>30 days after device removal, or, to induction of anesthesia for implant of a long-term device or heart transplant</time_frame>
    <description>Improvements in measures of end-organ function</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>All Patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients meeting the patient selection criteria will be treated with the CentriMag device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CentriMag Ventricular Assist System</intervention_name>
    <description>All patients will be treated with the CentriMag device for up to 30 days.</description>
    <arm_group_label>All Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 5 years to 16 years, inclusive&#xD;
&#xD;
          2. Inability to wean from cardiopulmonary bypass (CPB)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Body weight &lt; 20 kg&#xD;
&#xD;
          2. Severe aortic insufficiency&#xD;
&#xD;
          3. Unrestricted intra-cardiac communications (i.e. large VSD)&#xD;
&#xD;
          4. Pulmonary vascular resistance index (PVRI) &gt; 10 IU&#xD;
&#xD;
          5. Presence of DIC&#xD;
&#xD;
          6. On hemodialysis (excluding hemofiltration)&#xD;
&#xD;
          7. Contraindications to systemic anticoagulation&#xD;
&#xD;
          8. Active systemic infection unresponsive to antibiotics&#xD;
&#xD;
          9. Unresolved malignancy&#xD;
&#xD;
         10. On other investigational VAS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Poornima Sood</last_name>
    <role>Study Director</role>
    <affiliation>Thoratec Corporation/Abbott</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>July 27, 2010</study_first_submitted>
  <study_first_submitted_qc>July 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2010</study_first_posted>
  <last_update_submitted>January 28, 2019</last_update_submitted>
  <last_update_submitted_qc>January 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thoratec Corporation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

